pubmed-article:12181246 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12181246 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:12181246 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
pubmed-article:12181246 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
pubmed-article:12181246 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
pubmed-article:12181246 | lifeskim:mentions | umls-concept:C0050385 | lld:lifeskim |
pubmed-article:12181246 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
pubmed-article:12181246 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
pubmed-article:12181246 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:12181246 | pubmed:dateCreated | 2002-8-15 | lld:pubmed |
pubmed-article:12181246 | pubmed:abstractText | Docetaxel has yielded promising response rates as a component of doxorubicin-based combination schedules in patients with metastatic breast cancer, including docetaxel/doxorubicin and docetaxel/doxorubicin/cyclophosphamide (AC). This randomized two-stage phase II study was conducted to evaluate sequential treatment with docetaxel and AC as first-line treatment in patients with recurrent or metastatic breast cancer previously untreated with chemotherapy for metastatic disease. | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:language | eng | lld:pubmed |
pubmed-article:12181246 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12181246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12181246 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12181246 | pubmed:month | Aug | lld:pubmed |
pubmed-article:12181246 | pubmed:issn | 0923-7534 | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:AdamsJ CJC | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:IngleJ NJN | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:MichalakJ CJC | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:BaronA TAT | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:SumanV JVJ | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:PerezE AEA | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:GeeraertsLL | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:KuglerJ WJW | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:MaihleNN | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:HatfieldA KAK | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:KurossS ASA | lld:pubmed |
pubmed-article:12181246 | pubmed:author | pubmed-author:LafkyJ MJM | lld:pubmed |
pubmed-article:12181246 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12181246 | pubmed:volume | 13 | lld:pubmed |
pubmed-article:12181246 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12181246 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12181246 | pubmed:pagination | 1225-35 | lld:pubmed |
pubmed-article:12181246 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:meshHeading | pubmed-meshheading:12181246... | lld:pubmed |
pubmed-article:12181246 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:12181246 | pubmed:articleTitle | A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. | lld:pubmed |
pubmed-article:12181246 | pubmed:affiliation | Mayo Clinic and Mayo Foundation, Rochester, MN, USA. perez.edith@mayo.edu | lld:pubmed |
pubmed-article:12181246 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12181246 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:12181246 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:12181246 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:12181246 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:12181246 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:12181246 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |